;PMID: 8534263
;source_file_932.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..191] = [t:49..191]
;2)section:[e:195..215] = [t:195..215]
;3)section:[e:219..299] = [t:219..299]
;4)sentence:[e:303..522] = [t:303..522]
;5)sentence:[e:523..718] = [t:523..718]
;6)sentence:[e:719..950] = [t:719..950]
;7)sentence:[e:951..1066] = [t:951..1066]
;8)sentence:[e:1068..1224] = [t:1068..1224]
;9)sentence:[e:1226..1448] = [t:1226..1448]
;10)sentence:[e:1449..1556] = [t:1449..1556]
;11)sentence:[e:1557..1789] = [t:1557..1789]
;12)sentence:[e:1790..1920] = [t:1790..1920]
;13)sentence:[e:1922..2121] = [t:1922..2121]
;14)sentence:[e:2122..2397] = [t:2122..2397]
;15)section:[e:2401..2445] = [t:2401..2445]

;section 0 Span:0..43
;Biochem Pharmacol. 1996 Jan 12;51(1):15-20.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1996) (NNP:[24..27] Jan) (CD:[28..34] 12;51-LRB-)
        (CD:[34..35] 1) (-RRB-:[35..36] -RRB-) (CD:[36..39] :15) (::[39..40] -)
        (CD:[40..42] 20) (.:[42..43] .)))

;sentence 1 Span:49..191
;Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic 
;antidepressant drug desipramine and its primary oxidized metabolites.
;[74..90]:cyp450:"cytochromes P450"
;[122..141]:substance:"antidepressant drug"
;[142..153]:substance:"desipramine"
;[179..190]:substance:"metabolites"
(SENT
  (NP-HLN
    (NP (NN:[49..59] Inhibition))
    (PP (IN:[60..62] of)
      (NP (JJ:[63..73] microsomal)
         (NNS:[74..85] cytochromes) (NN:[86..90] P450)))
    (PP-LOC (IN:[91..93] in)
      (NP (NN:[94..97] rat) (NN:[98..103] liver)))
    (PP (IN:[104..106] by)
      (NP
        (NP
          (NP (DT:[107..110] the) (JJ:[111..120] tricyclic)
             (JJ:[122..136] antidepressant) (NN:[137..141] drug))
          (NP (NN:[142..153] desipramine)))
        (CC:[154..157] and)
        (NP (PRP$:[158..161] its) (JJ:[162..169] primary)
            (VBN:[170..178] oxidized) (NNS:[179..190] metabolites))))
    (.:[190..191] .)))

;section 2 Span:195..215
;McNeil CM, Murray M.
(SEC
  (FRAG (NNP:[195..201] McNeil) (NNP:[202..204] CM) (,:[204..205] ,)
        (NNP:[206..212] Murray) (NNP:[213..215] M.)))

;section 3 Span:219..299
;Department of Medicine, University of Sydney, Westmead Hospital, NSW,
;Australia.
(SEC
  (FRAG (NNP:[219..229] Department) (IN:[230..232] of) (NNP:[233..241] Medicine)
        (,:[241..242] ,) (NNP:[243..253] University) (IN:[254..256] of)
        (NNP:[257..263] Sydney) (,:[263..264] ,) (NNP:[265..273] Westmead)
        (NNP:[274..282] Hospital) (,:[282..283] ,) (NNP:[284..287] NSW)
        (,:[287..288] ,) (NNP:[289..298] Australia) (.:[298..299] .)))

;sentence 4 Span:303..522
;N-Monoalkyl substituted tricyclic antidepressants like desipramine (DES)
;undergo  cytochrome P450 (P450)-mediated biotransformation in liver to
;produce inhibitory  metabolite-intermediate (MI) complexes with the enzyme.
;[337..352]:substance:"antidepressants"
;[358..369]:substance:"desipramine"
;[371..374]:substance:"DES"
;[385..400]:cyp450:"cytochrome P450"
;[402..406]:cyp450:"P450"
;[467..505]:substance:"metabolite-intermediate (MI) complexes"
;[515..521]:cyp450:"enzyme"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (ADJP (NN:[303..314] N-Monoalkyl) (VBN:[315..326] substituted))
        (JJ:[327..336] tricyclic) (NNS:[337..352] antidepressants))
      (PP (IN:[353..357] like)
        (NP
          (NP (NN:[358..369] desipramine))
          (NP (-LRB-:[370..371] -LRB-) (NN:[371..374] DES)
              (-RRB-:[374..375] -RRB-)))))
    (VP (VBP:[376..383] undergo)
      (NP
        (ADJP
          (NML
            (NML (NN:[385..395] cytochrome) (NN:[396..400] P450))
            (NML (-LRB-:[401..402] -LRB-) (NN:[402..406] P450)
                 (-RRB-:[406..407] -RRB-)))
          (HYPH:[407..408] -) (VBN:[408..416] mediated))
        (NN:[417..434] biotransformation))
      (PP-LOC (IN:[435..437] in)
        (NP (NN:[438..443] liver)))
      (S-PRP
        (NP-SBJ-1 (-NONE-:[443..443] *))
        (VP (TO:[444..446] to)
          (VP (VB:[447..454] produce)
            (NP (JJ:[455..465] inhibitory)
              
              (NML
                (NML (NN:[467..477] metabolite) (HYPH:[477..478] -)
                     (NN:[478..490] intermediate))
                (NML (-LRB-:[491..492] -LRB-) (NN:[492..494] MI)
                     (-RRB-:[494..495] -RRB-)))
              (NNS:[496..505] complexes))
            (PP (IN:[506..510] with)
              (NP (DT:[511..514] the) (NN:[515..521] enzyme)))))))
    (.:[521..522] .)))

;sentence 5 Span:523..718
;However, additional  oxidation pathways that generate isolable metabolites
;have also been identified,  so that the relationship between MI complexation
;and total oxidative metabolism  is unclear.
;[586..597]:substance:"metabolites"
;[659..661]:substance:"MI"
(SENT
  (S
    (ADVP (RB:[523..530] However))
    (,:[530..531] ,)
    (NP-SBJ-2
      (NP (JJ:[532..542] additional) (NN:[544..553] oxidation)
          (NNS:[554..562] pathways))
      (SBAR
        (WHNP-1 (WDT:[563..567] that))
        (S
          (NP-SBJ-1 (-NONE-:[567..567] *T*))
          (VP (VBP:[568..576] generate)
            (NP (JJ:[577..585] isolable) (NNS:[586..597] metabolites))))))
    (VP (VBP:[598..602] have)
      (ADVP (RB:[603..607] also))
      (VP (VBN:[608..612] been)
        (VP (VBN:[613..623] identified)
          (NP-2 (-NONE-:[623..623] *))
          (,:[623..624] ,)
          (SBAR-ADV (IN:[626..628] so)
            (SBAR (IN:[629..633] that)
              (S
                (NP-SBJ
                  (NP (DT:[634..637] the) (NN:[638..650] relationship))
                  (PP (IN:[651..658] between)
                    (NP
                      (NP (NN:[659..661] MI) (NN:[662..674] complexation))
                      (CC:[675..678] and)
                      (NP (JJ:[679..684] total) (JJ:[685..694] oxidative)
                          (NN:[695..705] metabolism)))))
                (VP (VBZ:[707..709] is)
                  (ADJP-PRD (JJ:[710..717] unclear)))))))))
    (.:[717..718] .)))

;sentence 6 Span:719..950
;The present study investigated the capacity of DES and three  putative
;metabolites (2-hydroxy- and 10-hydroxy-DES and  N,N-didesmethylimipramine;
;DIDES) to elicit MI complexation and inhibit  P450-dependent activities in
;rat liver.
;[766..769]:substance:"DES"
;[790..801]:substance:"metabolites"
;[803..813]...[829..832]:substance:"2-hydroxy-"..."DES"
;[818..832]:substance:"10-hydroxy-DES"
;[838..863]:substance:"N,N-didesmethylimipramine"
;[865..870]:substance:"DIDES"
;[882..884]:substance:"MI"
;[911..915]:cyp450:"P450"
(SENT
  (S
    (NP-SBJ (DT:[719..722] The) (JJ:[723..730] present) (NN:[731..736] study))
    (VP (VBD:[737..749] investigated)
      (NP
        (NP (DT:[750..753] the) (NN:[754..762] capacity)
          (S-3 (-NONE-:[762..762] *ICH*)))
        (PP (IN:[763..765] of)
          (NP
            (NP (NN:[766..769] DES))
            (CC:[770..773] and)
            (NP
              (NP (CD:[774..779] three) (JJ:[781..789] putative)
                  (NNS:[790..801] metabolites))
              (PRN (-LRB-:[802..803] -LRB-)
                (NP
                  (NP (JJ:[803..812] 2-hydroxy) (HYPH:[812..813] -)
                    (NML-2 (-NONE-:[813..813] *P*)))
                  (CC:[814..817] and)
                  (NP (JJ:[818..828] 10-hydroxy) (HYPH:[828..829] -)
                    (NML-2 (NN:[829..832] DES)))
                  (CC:[833..836] and)
                  (NP
                    (NP (NN:[838..863] N,N-didesmethylimipramine))
                    (::[863..864] ;)
                    (NP (NN:[865..870] DIDES))))
                (-RRB-:[870..871] -RRB-)))))
        (S-3
          (NP-SBJ (-NONE-:[871..871] *))
          (VP (TO:[872..874] to)
            (VP
              (VP (VB:[875..881] elicit)
                (NP (NN:[882..884] MI) (NN:[885..897] complexation))
                (PP-LOC-1 (-NONE-:[897..897] *RNR*)))
              (CC:[898..901] and)
              (VP (VB:[902..909] inhibit)
                (NP
                  (ADJP (NN:[911..915] P450) (HYPH:[915..916] -)
                        (JJ:[916..925] dependent))
                  (NNS:[926..936] activities))
                (PP-LOC-1 (-NONE-:[936..936] *RNR*)))
              (PP-LOC-1 (IN:[937..939] in)
                (NP (NN:[940..943] rat) (NN:[944..949] liver))))))))
    (.:[949..950] .)))

;sentence 7 Span:951..1066
;MI complexation of P450 was produced by  DES, but not with the three
;metabolites, in NADPH-supplemented microsomes.
;[951..953]:substance:"MI"
;[970..974]:cyp450:"P450"
;[992..995]:substance:"DES"
;[1020..1031]:substance:"metabolites"
;[1036..1041]:substance:"NADPH"
(SENT
  (S
    (NP-SBJ-3
      (NP (NN:[951..953] MI) (NN:[954..966] complexation))
      (PP (IN:[967..969] of)
        (NP (NN:[970..974] P450))))
    (VP
      (VP (VBD:[975..978] was)
        (VP (VBN:[979..987] produced)
          (NP-3 (-NONE-:[987..987] *))
          (PP (IN:[988..990] by)
            (NP-LGS (NN:[992..995] DES)))
          (PP-LOC-2 (-NONE-:[995..995] *RNR*))))
      (,:[995..996] ,) (CC:[997..1000] but)
      (VP (RB:[1001..1004] not)
        (PP (IN:[1005..1009] with)
          (NP (DT:[1010..1013] the) (CD:[1014..1019] three)
              (NNS:[1020..1031] metabolites)))
        (PP-LOC-2 (-NONE-:[1031..1031] *RNR*)))
      (,:[1031..1032] ,)
      (PP-LOC-2 (IN:[1033..1035] in)
        (NP
          (ADJP (NN:[1036..1041] NADPH) (HYPH:[1041..1042] -)
                (VBN:[1042..1054] supplemented))
          (NNS:[1055..1065] microsomes))))
    (.:[1065..1066] .)))

;sentence 8 Span:1068..1224
;Consistent with this finding, inhibition of testosterone hydroxylation
;pathways  was enhanced markedly by prior incubation of DES with NADPH and
;microsomes.
;[1112..1124]:substance:"testosterone"
;[1194..1197]:substance:"DES"
;[1203..1208]:substance:"NADPH"
(SENT
  (ADJP
    (ADJP-ADV (JJ:[1068..1078] Consistent)
      (PP (IN:[1079..1083] with)
        (NP (DT:[1084..1088] this) (NN:[1089..1096] finding))))
    (,:[1096..1097] ,)
    (NP-SBJ-1
      (NP (NN:[1098..1108] inhibition))
      (PP (IN:[1109..1111] of)
        (NP (NN:[1112..1124] testosterone) (NN:[1125..1138] hydroxylation)
            (NNS:[1139..1147] pathways))))
    (VP (VBD:[1149..1152] was)
      (VP (VBN:[1153..1161] enhanced)
        (NP-1 (-NONE-:[1161..1161] *))
        (ADVP-MNR (RB:[1162..1170] markedly))
        (PP (IN:[1171..1173] by)
          (NP-LGS
            (NP (JJ:[1174..1179] prior) (NN:[1180..1190] incubation))
            (PP (IN:[1191..1193] of)
              (NP (NN:[1194..1197] DES)))
            (PP (IN:[1198..1202] with)
              (NP (NN:[1203..1208] NADPH) (CC:[1209..1212] and)
                  (NNS:[1213..1223] microsomes)))))))
    (.:[1223..1224] .)))

;sentence 9 Span:1226..1448
;Direct addition of DIDES to incubations resulted in significant inhibition of
; P450 activities (IC50s of 35 and 29 microM against estradiol 6 beta- and 16 
;alpha-hydroxylation mediated by P450s 3A2 and 2C11, respectively).
;[1245..1250]:substance:"DIDES"
;[1305..1309]:cyp450:"P450"
;[1322..1327]:quantitative-name:"IC50s"
;[1331..1333]:quantitative-value:"35"
;[1338..1340]:quantitative-value:"29"
;[1341..1347]:quantitative-units:"microM"
;[1356..1365]:substance:"estradiol"
;[1414..1423]:cyp450:"P450s 3A2"
;[1414..1419]...[1428..1432]:cyp450:"P450s"..."2C11"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1226..1232] Direct) (NN:[1233..1241] addition))
      (PP (IN:[1242..1244] of)
        (NP (NN:[1245..1250] DIDES)))
      (PP (TO:[1251..1253] to)
        (NP (NNS:[1254..1265] incubations))))
    (VP (VBD:[1266..1274] resulted)
      (PP-CLR (IN:[1275..1277] in)
        (NP
          (NP (JJ:[1278..1289] significant) (NN:[1290..1300] inhibition))
          (PP (IN:[1301..1303] of)
            (NP
              (NP (NN:[1305..1309] P450) (NNS:[1310..1320] activities))
              (PRN (-LRB-:[1321..1322] -LRB-)
                (FRAG
                  (NP
                    (NP (NNS:[1322..1327] IC50s))
                    (PP (IN:[1328..1330] of)
                      (NP
                        (NP (CD:[1331..1333] 35)
                          (NML-4 (-NONE-:[1333..1333] *P*)))
                        (CC:[1334..1337] and)
                        (NP (CD:[1338..1340] 29)
                          (NML-4 (NN:[1341..1347] microM))))))
                  (PP (IN:[1348..1355] against)
                    (NP
                      (NP
                        (NP
                          (NML-3 (NN:[1356..1365] estradiol))
                          (NML (CD:[1366..1367] 6) (SYM:[1368..1372] beta))
                          (HYPH:[1372..1373] -)
                          (NML-2 (-NONE-:[1373..1373] *P*)))
                        (CC:[1374..1377] and)
                        (NP
                          (NML-3 (-NONE-:[1377..1377] *P*))
                          (NML (CD:[1378..1380] 16) (SYM:[1382..1387] alpha))
                          (HYPH:[1387..1388] -)
                          (NML-2 (NN:[1388..1401] hydroxylation))))
                      (VP (VBN:[1402..1410] mediated)
                        (NP (-NONE-:[1410..1410] *))
                        (PP (IN:[1411..1413] by)
                          (NP-LGS
                            (NP
                              (NML-1 (NNS:[1414..1419] P450s))
                              (NN:[1420..1423] 3A2))
                            (CC:[1424..1427] and)
                            (NP
                              (NML-1 (-NONE-:[1427..1427] *P*))
                              (NN:[1428..1432] 2C11))))
                        (,:[1432..1433] ,)
                        (ADVP (RB:[1434..1446] respectively))))))
                (-RRB-:[1446..1447] -RRB-)))))))
    (.:[1447..1448] .)))

;sentence 10 Span:1449..1556
;Neither  2-hydroxy- nor 10-hydroxy-DES directly inhibited testosterone
;hydroxylation  (IC50s > 100 microM).
;[1458..1468]...[1484..1487]:substance:"2-hydroxy-"..."DES"
;[1473..1487]:substance:"10-hydroxy-DES"
;[1507..1519]:substance:"testosterone"
;[1536..1541]:quantitative-name:"IC50s"
;[1542..1547]:quantitative-value:"> 100"
;[1548..1554]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (CC:[1449..1456] Neither)
      (NP (JJ:[1458..1467] 2-hydroxy) (HYPH:[1467..1468] -)
        (NML-1 (-NONE-:[1468..1468] *P*)))
      (CC:[1469..1472] nor)
      (NP (JJ:[1473..1483] 10-hydroxy) (HYPH:[1483..1484] -)
        (NML-1 (NN:[1484..1487] DES))))
    (ADVP-MNR (RB:[1488..1496] directly))
    (VP (VBD:[1497..1506] inhibited)
      (NP (NN:[1507..1519] testosterone) (NN:[1520..1533] hydroxylation))
      (PRN (-LRB-:[1535..1536] -LRB-)
        (S
          (NP-SBJ (NNS:[1536..1541] IC50s))
          (VP (SYM:[1542..1543] >)
            (NP (CD:[1544..1547] 100) (NN:[1548..1554] microM))))
        (-RRB-:[1554..1555] -RRB-)))
    (.:[1555..1556] .)))

;sentence 11 Span:1557..1789
;However, after a preincubation step between these  metabolites and
;NADPH-fortified microsomes, enhanced inhibition of reactions  mediated by
;P450 3A2 and P450 2C11/2A1 was produced by 2-hydroxy-DES and  10-hydroxy-DES,
;respectively.
;[1608..1619]:substance:"metabolites"
;[1624..1629]:substance:"NADPH"
;[1698..1706]:cyp450:"P450 3A2"
;[1711..1720]:cyp450:"P450 2C11"
;[1711..1715]...[1721..1724]:cyp450:"P450"..."2A1"
;[1741..1754]:substance:"2-hydroxy-DES"
;[1760..1774]:substance:"10-hydroxy-DES"
(SENT
  (S
    (ADVP (RB:[1557..1564] However))
    (,:[1564..1565] ,)
    (PP-TMP (IN:[1566..1571] after)
      (NP
        (NP (DT:[1572..1573] a) (NN:[1574..1587] preincubation)
            (NN:[1588..1592] step))
        (PP (IN:[1593..1600] between)
          (NP
            (NP (DT:[1601..1606] these) (NNS:[1608..1619] metabolites))
            (CC:[1620..1623] and)
            (NP
              (ADJP (NN:[1624..1629] NADPH) (HYPH:[1629..1630] -)
                    (VBN:[1630..1639] fortified))
              (NNS:[1640..1650] microsomes))))))
    (,:[1650..1651] ,)
    (NP-SBJ-2
      (NP (VBN:[1652..1660] enhanced) (NN:[1661..1671] inhibition))
      (PP (IN:[1672..1674] of)
        (NP
          (NP (NNS:[1675..1684] reactions))
          (VP (VBN:[1686..1694] mediated)
            (NP (-NONE-:[1694..1694] *))
            (PP (IN:[1695..1697] by)
              (NP-LGS
                (NP (NN:[1698..1702] P450) (NN:[1703..1706] 3A2))
                (CC:[1707..1710] and)
                (NP
                  (NP
                    (NML-1 (NN:[1711..1715] P450))
                    (NN:[1716..1720] 2C11))
                  (SYM:[1720..1721] /)
                  (NP
                    (NML-1 (-NONE-:[1721..1721] *P*))
                    (NN:[1721..1724] 2A1)))))))))
    (VP (VBD:[1725..1728] was)
      (VP (VBN:[1729..1737] produced)
        (NP-2 (-NONE-:[1737..1737] *))
        (PP (IN:[1738..1740] by)
          (NP-LGS (NN:[1741..1754] 2-hydroxy-DES) (CC:[1755..1758] and)
                  (NN:[1760..1774] 10-hydroxy-DES)))
        (,:[1774..1775] ,)
        (ADVP (RB:[1776..1788] respectively))))
    (.:[1788..1789] .)))

;sentence 12 Span:1790..1920
;Metabolism of DES to DIDES and 2-hydroxy-DES was  estimated as 7.77 +/- 0.48
;nmol/mg protein/hr (10-hydroxy-DES was not detected).
;[1804..1807]:substance:"DES"
;[1811..1816]:substance:"DIDES"
;[1821..1834]:substance:"2-hydroxy-DES"
;[1853..1866]:quantitative-value:"7.77 +/- 0.48"
;[1867..1885]:quantitative-units:"nmol/mg protein/hr"
;[1887..1901]:substance:"10-hydroxy-DES"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1790..1800] Metabolism))
      (PP (IN:[1801..1803] of)
        (NP (NN:[1804..1807] DES)))
      (PP (TO:[1808..1810] to)
        (NP (NN:[1811..1816] DIDES) (CC:[1817..1820] and)
            (NN:[1821..1834] 2-hydroxy-DES))))
    (VP (VBD:[1835..1838] was)
      (VP (VBN:[1840..1849] estimated)
        (NP-2 (-NONE-:[1849..1849] *))
        (PP (IN:[1850..1852] as)
          (NP
            (NP
              (QP (CD:[1853..1857] 7.77) (SYM:[1858..1861] +/-)
                  (CD:[1862..1866] 0.48))
              (NN:[1867..1871] nmol))
            (PP (SYM:[1871..1872] /)
              (NP
                (NP (NN:[1872..1874] mg))
                (NP (NN:[1875..1882] protein))))
            (PP (SYM:[1882..1883] /)
              (NP (NN:[1883..1885] hr)))))
        (PRN (-LRB-:[1886..1887] -LRB-)
          (S
            (NP-SBJ-1 (NN:[1887..1901] 10-hydroxy-DES))
            (VP (VBD:[1902..1905] was) (RB:[1906..1909] not)
              (VP (VBN:[1910..1918] detected)
                (NP-1 (-NONE-:[1918..1918] *)))))
          (-RRB-:[1918..1919] -RRB-))))
    (.:[1919..1920] .)))

;sentence 13 Span:1922..2121
;It is likely that secondary oxidized metabolites derived from 2-hydroxy-DES,
;as  well as the primary metabolite DIDES, may contribute to the inhibition of
;P450  activity during DES biotransformation.
;[1959..1970]:substance:"metabolites"
;[1984..1997]:substance:"2-hydroxy-DES"
;[2023..2033]:substance:"metabolite"
;[2034..2039]:substance:"DIDES"
;[2077..2081]:cyp450:"P450"
;[2099..2102]:substance:"DES"
(SENT
  (S
    (NP-SBJ (PRP:[1922..1924] It))
    (VP (VBZ:[1925..1927] is)
      (ADJP-PRD (JJ:[1928..1934] likely)
        (SBAR (IN:[1935..1939] that)
          (S
            (NP-SBJ
              (NP
                (NP (JJ:[1940..1949] secondary) (VBN:[1950..1958] oxidized)
                    (NNS:[1959..1970] metabolites))
                (VP (VBN:[1971..1978] derived)
                  (NP (-NONE-:[1978..1978] *))
                  (PP (IN:[1979..1983] from)
                    (NP (NN:[1984..1997] 2-hydroxy-DES) (,:[1997..1998] ,)))))
              (CONJP (RB:[1999..2001] as) (RB:[2003..2007] well)
                     (IN:[2008..2010] as))
              (NP
                (NP (DT:[2011..2014] the) (JJ:[2015..2022] primary)
                    (NN:[2023..2033] metabolite))
                (NP (NN:[2034..2039] DIDES))))
            (,:[2039..2040] ,)
            (VP (MD:[2041..2044] may)
              (VP (VB:[2045..2055] contribute)
                (PP-CLR (TO:[2056..2058] to)
                  (NP
                    (NP (DT:[2059..2062] the) (NN:[2063..2073] inhibition))
                    (PP (IN:[2074..2076] of)
                      (NP
                        (NP (NN:[2077..2081] P450) (NN:[2083..2091] activity))
                        (PP-TMP (IN:[2092..2098] during)
                          (NP (NN:[2099..2102] DES)
                              (NN:[2103..2120] biotransformation)))))))))))))
    (.:[2120..2121] .)))

;sentence 14 Span:2122..2397
;These results indicate that the  2-hydroxy-, 10-hydroxy-, and
;N-desmethyl-metabolites of DES are not involved in  MI complexation, but
;complexation is not the sole mechanism by which DES  inhibits microsomal drug
;oxidation that may lead to pharmacokinetic drug  interactions.
;[2155..2165]...[2196..2207]:substance:"2-hydroxy-"..."metabolites"
;[2167..2178]...[2196..2207]:substance:"10-hydroxy-"..."metabolites"
;[2211..2214]:substance:"DES"
;[2236..2238]:substance:"MI"
;[2305..2308]:substance:"DES"
;[2330..2334]:substance:"drug"
;[2378..2382]:substance:"drug"
(SENT
  (S
    (NP-SBJ (DT:[2122..2127] These) (NNS:[2128..2135] results))
    (VP (VBP:[2136..2144] indicate)
      (SBAR (IN:[2145..2149] that)
        (S
          (S
            (NP-SBJ-4
              (NP (DT:[2150..2153] the)
                (NML
                  (NML (JJ:[2155..2164] 2-hydroxy) (HYPH:[2164..2165] -)
                    (NML-3 (-NONE-:[2165..2165] *P*)))
                  (,:[2165..2166] ,)
                  (NML (JJ:[2167..2177] 10-hydroxy) (HYPH:[2177..2178] -)
                    (NML-3 (-NONE-:[2178..2178] *P*)))
                  (,:[2178..2179] ,) (CC:[2180..2183] and)
                  (NML (NN:[2184..2195] N-desmethyl) (HYPH:[2195..2196] -)
                    (NML-3 (NNS:[2196..2207] metabolites)))))
              (PP (IN:[2208..2210] of)
                (NP (NN:[2211..2214] DES))))
            (VP (VBP:[2215..2218] are) (RB:[2219..2222] not)
              (VP (VBN:[2223..2231] involved)
                (NP-4 (-NONE-:[2231..2231] *))
                (PP-CLR (IN:[2232..2234] in)
                  (NP (NN:[2236..2238] MI) (NN:[2239..2251] complexation))))))
          (,:[2251..2252] ,) (CC:[2253..2256] but)
          (S
            (NP-SBJ (NN:[2257..2269] complexation))
            (VP (VBZ:[2270..2272] is) (RB:[2273..2276] not)
              (NP-PRD
                (NP (DT:[2277..2280] the) (JJ:[2281..2285] sole)
                    (NN:[2286..2295] mechanism))
                (SBAR
                  (WHPP-2 (IN:[2296..2298] by)
                    (WHNP (WDT:[2299..2304] which)))
                  (S
                    (NP-SBJ (NN:[2305..2308] DES))
                    (VP (VBZ:[2310..2318] inhibits)
                      (PP-MNR-2 (-NONE-:[2318..2318] *T*))
                      (NP
                        (NP (JJ:[2319..2329] microsomal) (NN:[2330..2334] drug)
                            (NN:[2335..2344] oxidation))
                        (SBAR
                          (WHNP-1 (WDT:[2345..2349] that))
                          (S
                            (NP-SBJ-1 (-NONE-:[2349..2349] *T*))
                            (VP (MD:[2350..2353] may)
                              (VP (VB:[2354..2358] lead)
                                (PP-CLR (TO:[2359..2361] to)
                                  (NP (JJ:[2362..2377] pharmacokinetic)
                                      (NN:[2378..2382] drug)
                                      (NNS:[2384..2396] interactions)))))))))))))))))
    (.:[2396..2397] .)))

;section 15 Span:2401..2445
;PMID: 8534263 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2401..2405] PMID) (::[2405..2406] :) (CD:[2407..2414] 8534263)
        (NN:[2415..2416] -LSB-) (NNP:[2416..2422] PubMed) (::[2423..2424] -)
        (NN:[2425..2432] indexed) (IN:[2433..2436] for)
        (NNP:[2437..2445] MEDLINE-RSB-)))
